Navigation Links
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
Date:12/9/2009

RICHMOND, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

The preliminary data were from the first subjects enrolled in Sangamo's Phase 2 clinical trial, SB-509-801, and demonstrate an approximate doubling of frequency of improved muscle function in subjects with ALS who received two treatments of SB-509 (32%) compared to matched historic controls (17%). In early stage ALS clinical trials, an historic control is frequently used rather than a placebo to maximize the number of subjects receiving the drug.

Muscle function was assessed by muscle manual testing (MMT), a commonly used ALS endpoint which uses a manual method of functional assessment of 34 muscles over the whole body. In addition, a subset of subjects that showed an increase in muscle function over this period also demonstrated improvement in one or more additional end-points. These end-points include the Revised ALS Functional Rating Scale (ALSFRS-R) which is a validated rating instrument for monitoring the quality of life and progression of disability in patients with ALS and whose scores correlate significantly with survival, and forced vital capacity (FVC), a measure of lung function.

"We desperately need new therapeutics that will alter the relentless deterioration of muscle function that is characteristic of ALS," commented Jeffrey Rothstein, M.D., Ph.D., Director of the Robert Packard Center for ALS Research, Co-Director of the MDA/ALS Clinic and professor of Neurology at the Johns Hopkins University S
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo Announces Closing of Common Stock Offering
2. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
3. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
5. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. (NYSE ... closing of its offering of $125 million aggregate principal ... "Notes").  The Notes were offered and sold only to ... Securities Act of 1933, as amended (the "Securities Act"). ... rate of 3.75% per year, payable semiannually in arrears ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... - GenVec, Inc.,(Nasdaq:GNVC) announced today data from ... of the American Association of Cancer,Research (AACR) ... systems,to deliver the gene for tumor necrosis ... (TNFerade),is an adenovector, or DNA carrier, which ...
... 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the presentation ... trial of the triplet combination of TELCYTA(R),(canfosfamide ... treatment of advanced non-small cell lung cancer. ... in both progression-free survival and overall survival,in ...
Cached Medicine Technology:GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 2GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Emergo Group, ... in 26 countries in North and South America, Europe, ... responses from industry participants for its 2015 Medical Device ... order to identify upcoming business and market trends as ... , The survey targets areas including:, , ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 At the ... organizations AutismOne and Focus Autism ... attendees with research on the effects of toxins to ... and intervention information. , Luminaries such as Dr. ... from abroad with esteemed, credentialed colleagues of the United ...
(Date:12/15/2014)... 2014 Kenmode Precision Metal Stamping has ... Director of Quality Assurance. He brings more than ... and certifications for manufacturers in the U.S. and abroad. ... Quality Manager at Sonoco Products Company in the Protective ... and Quality Assurance Manager for Prince Industries, all in ...
Breaking Medicine News(10 mins):Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
... , CHICAGO , Jan. 28 Code ... Express, Inc., a portfolio investment of CHS Private Equity V ... New York -based private equity firm.   , Suture Express ... medical and surgical products.  Suture Express offers over 1,600 acute ...
... is well known that smokers damage their health by ... Central,s open access journal Environmental Health has ... environmental tobacco smoke, contrary to the prevailing assumption that ... incurred by actually smoking. Maria Teresa Piccardo worked ...
... ... Washington With Fame 101 , ... Portland, Oregon (Vocus) January 28, 2010 -- Celebrity doctors attract high-value patients, get book deals, ... they win that celebrity status? Publicity and branding experts report high-visibility doctors are as adept ...
... DENVER , Jan. 28 Grubb & ... entered into an agreement to acquire Highlands Ranch Medical Pavilion, ... Denver suburb of Highlands Ranch .  The acquisition ... other requirements as detailed in the agreement.   , Located ...
... , Jan. 28 Care Investment Trust Inc. (NYSE: ... investment and finance company formed to invest in healthcare-related real estate ... (the "Plan"), previously approved by the Company,s Board of Directors on ... a special meeting called for that purpose.  Approval of the Plan ...
... CHICAGO , Jan. 28 In his first ... our nation, but fear of root canals should not be one ... the "unpopular" nature of root canal procedures. The AAE, which represents ... feared, and hopes the President and all Americans become better informed ...
Cached Medicine News:Health News:Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc. 2Health News:Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc. 3Health News:Doctors: Memorable or Forgettable? 4 Steps to a High Visibility Practice 2Health News:Doctors: Memorable or Forgettable? 4 Steps to a High Visibility Practice 3Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 2Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 3Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 4Health News:Care Investment Trust Inc. Announces Stockholder Approval of Plan of Liquidation 2Health News:President's 'As Popular as a Root Canal' Comment Misses Mark 2Health News:President's 'As Popular as a Root Canal' Comment Misses Mark 3
... The Cholestech LDX System, using patented, innovative ... glucose and ALT in only 5 minutes ... ALT test, you can get immediate liver ... capabilities is not the only advantage to ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: